Risk factors
Coya Therapeutics (COYA) risk factors
Item 1A of every Coya Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors100 risks4 new6 dropped8 reworded
Coya Therapeutics discloses cash runway into the second half of 2027 with $46.8 million as of December 31, 2025 plus an $11.1 million January 2026 offering. Net loss increased to $21.2 million for 2025, bringing the accumulated deficit to $62.0 million. Supply chain and manufacturing dependencies for COYA 201, COYA 206, and COYA 301 are newly detailed.
Filed Mar 16, 2026 - FY2024 10-K risk factors102 risks
Clinical-stage biopharmaceutical company focused on regulatory T cell technologies with no approved commercial products and a history of operating losses.
Filed Mar 18, 2025